开窗/分支血管腔内主动脉修复术后II型及复杂内漏的特征与管理
单中心前瞻性收集的335例开窗/分支血管腔内主动脉修复术回顾性分析显示,37%患者发生内漏,其中II型最常见(占60%),20%的II型内漏伴瘤囊增大;针对II型内漏的干预常导致重新分类为复杂内漏,即合并CT血管造影和/或双功超声未发现的I型或III型内漏。
要点
- 开窗/分支血管腔内主动脉修复术后37%患者发生内漏,II型内漏占60%。
- 20%的II型内漏伴瘤囊增大,其中75%接受了干预。
- 干预时40%的II型内漏被重新分类为复杂内漏(合并I型或III型)。
核心结论
- 近半数接受开窗/分支血管腔内主动脉修复术的患者发生内漏,多数为II型,近五分之一伴瘤囊扩张。
- 针对II型内漏的干预常导致重新分类为复杂内漏,即合并CT血管造影和/或双功超声未发现的I型或III型内漏。
- 需进一步研究确定复杂动脉瘤修复的主要治疗目标是瘤囊稳定还是瘤囊回缩,这将影响无创内漏分类的重要性和II型内漏的干预阈值。
研究设计与样本
- 单中心前瞻性收集的研究性器械豁免临床试验(G130210)数据,回顾性分析2014年至2021年连续335例开窗/分支血管腔内主动脉修复术,平均随访2.5±1.5年。
- 内漏按类型、检出时间和处理方式分类;原发性内漏定义为完成影像或首次术后影像即存在,继发性为后续影像出现,复发性为成功解决后再次出现。
- 干预指征为I型或III型内漏或任何伴瘤囊增长>5 mm的内漏;技术成功定义为手术结束时瘤囊内无血流。
主要发现
- 335例开窗/分支血管腔内主动脉修复术中,125例(37%)发生166次内漏(原发性81次、继发性72次、复发性13次)。
- 125例患者中50例(占患者40%)针对60次内漏接受了71次干预。
- II型内漏最常见(n=100,60%),其中20次于索引手术中发现,12次(60%)在30天随访前解决。
- 100次II型内漏中20次(20%;原发性12次、继发性5次、复发性3次)伴瘤囊增长,其中15次(75%)接受了干预。
- 干预时6次(40%)被重新分类为复杂内漏,合并I型或III型内漏;内漏治疗初始技术成功率为96%(68/71);13次复发均与复杂内漏相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Endoleaks are more common after fenestrated/branched endovascular aneurysm repair (F/B-EVAR) than infrarenal EVAR secondary to the length of aortic coverage and number of component junctions. Although reports have focused on type I and III endoleaks, less is known regarding type II endoleaks after F/B-EVAR. We hypothesized that type II endoleaks would be common and often complex (associated with additional endoleak types), given the potential for multiple inflow and outflow sources. We sought to describe the incidence and complexity of type II endoleaks after F/B-EVAR. METHODS: F/B-EVAR data prospectively collected at a single institution in an investigational device exemption clinical trial (G130210) were retrospectively analyzed (2014-2021). Endoleaks were characterized by type, time to detection, and management. Primary endoleaks were defined as those present on completion imaging or at first postoperative imaging, and secondary were those on subsequent imaging. Recurrent endoleaks were those that developed after a successfully resolved endoleak. Reinterventions were considered for type I or III endoleaks or any endoleak associated with sac growth >5 mm. Technical success defined as the absence of flow in the aneurysm sac at procedure conclusion and methods of intervention were captured. RESULTS: Among 335 consecutive F/B-EVARs (mean ± standard deviation follow-up: 2.5 ± 1.5 years), 125 patients (37%) experienced 166 endoleaks (81 primary, 72 secondary, and 13 recurrent). Of these 125 patients, 50 (40% of patients) underwent 71 interventions for 60 endoleaks. Type II endoleaks were the most frequent (n = 100, 60%), with 20 identified during the index procedure, 12 (60%) of which resolved before 30-day follow-up. Of the 100 type II endoleaks, 20 (20%; 12 primary, 5 secondary, and 3 recurrent) were associated with sac growth; 15 (75%) of those with associated sac growth underwent intervention. At intervention, 6 (40%) were reclassified as complex, with a concomitant type I or type III endoleak. Initial technical success for endoleak treatment was 96% (68 of 71). There were 13 recurrences, all of which were associated with complex endoleaks. CONCLUSIONS: Nearly half of the patients who underwent F/B-EVAR experienced an endoleak. The majority were classified as type II, with nearly a fifth associated with sac expansion. Interventions for a type II endoleak frequently led to reclassification as complex, with a concomitant type I or III endoleak not appreciated on computed tomography angiography and/or duplex. Further study is needed to determine if the primary treatment goal for complex aneurysm repair is sac stability or sac regression, as this would inform both the importance of properly classifying endoleaks noninvasively and the intervention threshold for managing type II endoleaks.
引用
- Marecki HL, Finnesgard EJ, Nuvvula S, et al. Characterization and management of type II and complex endoleaks after fenestrated/branched endovascular aneurysm repair. J Vasc Surg. 2023. PMID: 36889609. doi:10.1016/j.jvs.2023.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。